Please ensure Javascript is enabled for purposes of website accessibility

Could Affimed Be a Millionaire-Maker Stock?

By Cory Renauer – May 14, 2021 at 6:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech stock has already produced some big returns this year.

Shares of Affimed (AFMD -2.00%) have been soaring on the back of positive clinical trial results for an experimental cancer therapy that could be worth billions. The stock has already gained around 61% this year, but some biotech investors think it could climb much higher.

Can Affimed really make a millionaire out of the average investor? To find out, we'll need to look at what's driven the stock to recent peaks and what still needs to happen before it can make you rich.

An investor at her computer.

Image source: Getty Images.

A revised approach

Affimed's heavily invested in a new approach to treating cancer that involves engaging a component of immune cells known as natural killer (NK) cells. The company's lead candidate at the moment, AFM13, is a two-faced antibody that binds to CD30, a protein often found on the surface of cancer cells, while its other side engages NK cells.

There are a lot of ins and outs when it comes to NK cells, but the important thing Affimed investors need to remember is that the cells can facilitate powerful immune responses to tumors. Getting them to attack cancer cells on command, though, has been more challenging than hoped.

Affimed initially began developing AFM13 as a relatively simple antibody, but the results were less than exciting. The company is back with an infusion of NK cells that are already bound to AFM13 and the new formulation appears to work like a charm. 

Why Affimed stock has soared

Shares of this biotech skyrocketed in April after the company showed investors impressive clinical trial results from the first few patients treated with AFM13-bound NK cells in a phase 1 dose determination study. Treatment with this version of AFM13 shrank tumors for all four Hodgkin's lymphoma patients treated so far.

Four out of four is a pretty good result for newly diagnosed lymphoma patients, but these trial volunteers already had lots of experience with different treatments. The least-experienced patient in the group had tumors that continued growing after four previous lines of therapy. Two of the four patients achieved complete remission after treatment with AFM13, including one who had been treated, unsuccessfully, with an experimental therapy made of CD30-directed T-cells.

So far, the new approach appears relatively well tolerated. Nasty side effects associated with other cellular cancer treatments haven't been observed among patients taking AFM13-bound NK cells.

Cellular cancer therapies like Yescarta from Gilead Sciences (NASDAQ: GILD) use specially engineered T-cells that were initially harvested from patients themselves. This convoluted process has limited their uptake, but this won't be an issue for AFM13. Instead of repeating a complex manufacturing process for each patient, Affimed can use AFM13 bound to a one-size-fits-all line of NK cells. 

Reasons to wait?

Using NK cells to facilitate an immune response around tumors that had previously avoided attention isn't a new concept. You should also know that initial successes with small patient groups have a disappointing tendency to drop off as cancer studies enroll more patients. 

The risk of cancer generally increases with age but it's also much harder to elicit responses from older patients. Four measurable responses from the first four patients dosed with a new candidate is an amazing start, but it's important to realize the oldest patient treated with AFM13 so far was just 53 years old.

As a clinical-stage biotech, Affimed doesn't have a reliable source of revenue yet. This means the company's $1.1 billion market cap could come crashing down if more recently enrolled patients don't exhibit similar responses.

Worth a shot

Affimed's market cap has swollen to 10 figures, but the stock at this price will seem like a terrific bargain if NK cells pre-complexed with AFMD13 continue to impress. Until we see confirmation from more patients, though, investors want to approach this stock with caution.

This biotech has what it takes to make millionaires out of everyday investors. Just be sure to keep shares of its still-risky stock in a well-diversified portfolio.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Affimed Therapeutics Stock Quote
Affimed Therapeutics
$1.96 (-2.00%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.